ISAB: Revenue fell, losses widened, but order intake and cash position improved after new financing

About this update from Inhalation Sciences Sweden Ab

Revenue and profitability declined sharply year-over-year, but order intake increased and a SEK 12m rights issue strengthened liquidity. Strategic review with PharmaVentures and expanded marketing aim to drive future growth and maximize technology value.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Inhalation Sciences Sweden Ab